[1]李 森,李去病,李 毅.巴林平胶囊联合化疗治疗恶性淋巴瘤临床研究[J].陕西中医,2024,(7):913-917.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.011]
　LI Sen,LI Qubing,LI Yi.Clinical research on Balinping capsule combined with chemotherapy in treatment of malignant lymphoma[J].,2024,(7):913-917.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.011]
点击复制

巴林平胶囊联合化疗治疗恶性淋巴瘤临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年7期
页码:
913-917
栏目:
临床研究
出版日期:
2024-07-05

文章信息/Info

Title:
Clinical research on Balinping capsule combined with chemotherapy in treatment of malignant lymphoma
作者:
李 森1; 李去病1; 李 毅2
(1.咸阳肿瘤医院,陕西 咸阳 712044; 2.陕西中医药大学附属医院,陕西 咸阳 712046)
Author(s):
LI Sen; LI Qubing; LI Yi
(Xianyang Tumor Hospital,Xianyang 712044,China)
关键词:
恶性淋巴瘤;  巴林平胶囊;  CHOP方案;  中医证候积分;  乳酸脱氢酶
Keywords:
Malignant lymphoma;  Balinping capsules;  CHOP regimen;  Traditional Chinese medicine syndrome score;  Lactate dehydrogenase
分类号:
R 273
DOI:
DOI:10.3969/j.issn.1000-7369.2024.07.011
文献标志码:
A
摘要:
目的:研究巴林平胶囊联合CHOP(环磷酰胺+多柔比星+长春新碱+泼尼松龙)方案治疗恶性淋巴瘤的疗效。方法:将72例恶性淋巴瘤患者随机分为试验组、对照组,每组36例,试验组患者在应用CHOP化疗方案的基础上服用巴林平胶囊,对照组患者常规使用CHOP方案化疗。结果:肿瘤客观疗效分析显示,试验组的有效率为83.33%,对照组有效率为63.89%。中医证候疗效分析显示,试验组显著改善率为58.33%,对照组为33.33%,试验组疗效优于对照组。治疗前后两组中医证候积分比较,恶核累累、形体消瘦、神疲乏力等主要症状,发热盗汗、腹胀、口渴咽干、大便干结等次要症状以及总积分均有明显改善,试验组疗效优于对照组(P<0.05)。纳呆、失眠多梦等症状两组间比较,差异无统计学意义(均P>0.05)。两组治疗后的疗效优于治疗前,试验组疗效优于对照组。两组治疗前后血液学检查结果比较,试验组治疗后白细胞(WBC)、粒细胞(NE)、血小板(PLT)计数高于对照组(P<0.05)。两组治疗后血生化指标比较,肌酸激酶同工酶(CK-MB)、谷丙转酶(ALT)水平均有所升高,试验组低于对照组,差异有统计学意义(均P<0.05)。治疗后两组血清乳酸脱氢酶(LDH)降低,试验组LDH低于对照组,差异有统计学意义(P<0.05)。结论:巴林平胶囊联合化疗治疗恶性淋巴瘤疗效较好,可有效改善患者临床症状和预后,提升化疗药物疗效,降低不良反应,效果优于单纯使用化疗方案。
Abstract:
Objective:To study clinical efficacy of Balinping capsules combined with CHOP(cyclophosphamide+doxorubicin+vincristine+prednisolone)chemotherapy in treatment of malignant lymphoma.Methods:72 patients with malignant lymphoma were randomly divided into experimental group and control group,with 36 cases in each group.Patients in the experimental group received Balinipine capsules in addition to CHOP chemotherapy regimen,while patients in the control group received conventional CHOP chemotherapy regimen.Results:The objective efficacy analysis of tumors showed that total effective rate of the experimental group was 83.33%,and the control group 63.89%.The analysis of traditional Chinese medicine syndrome efficacy showed significant improvement rate of 58.33% in the experimental group and 33.33% in the control group,with statistical significance between the two groups.The therapeutic effect of the experimental group was better than that in the control group.The comparison of traditional Chinese medicine syndrome scores between the two groups before and after treatment showed that the main symptoms,such as accumulation of evilnuclei,emaciation,and fatigue,as well as secondary symptoms such as fever,night sweating,abdominal distension,thirst and dry throat,and dry stool,as well as the total scorewere significantly improved.The therapeutic effect of the experimental group were better than that in the control group(all P<0.05).There was no significant difference(P>0.05)between the two groups in terms of symptoms such as indigestion and loss of appetite,insomnia and excessive dreaming.There was significant difference in the comparison of disease severity before and after treatment through statistical analysis(P<0.05).After treatment,efficacy of the two groups was significantly better than before,and efficacy of the experimental group was better than that in the control group.Comparison of hematology examination results before and after treatment between the two groups showed that the experimental group had higher counts of white blood cells(WBC),granulocytes(NE),and platelets(PLT)than the control group after treatment(all P<0.05).After treatment,the levels of blood biochemical indicators,like creatine kinase isoenzyme(CK-MB)and alanine aminotransferase(ALT)increased in both groups.The elevated levels in the experimental group were lower than those in the control group,and the difference between the two groups were statistically significant(all P<0.05).After treatment,the levels of lactate dehydrogenase(LDH)in the serum of the two groups significantly decreased(P<0.05).LDH levels in the experimental group were lower than those in the control group(P<0.05).Conclusion:The combination of Balinping capsules and chemotherapy has definite therapeutic effect on malignant lymphoma,which can effectively improve the clinical symptoms and prognosis of patients,enhance efficacy of chemotherapy drugs,reduce toxic side effects,and superior to the use of chemotherapy alone.

参考文献/References:

[1] 顾世成,叶宝东.恶性淋巴瘤的中医辨治思考[J].浙江中医杂志,2021,56(8):598-599.
[2] 惠逸帆,倪海雯,程海波.基于癌毒病机理论辨治恶性淋巴瘤探析[J].中国中医药信息杂志,2023,30(3):142-145.
[3] 刘珂,李仝,苑忠霞,等.基于窠囊理论辨治恶性淋巴瘤[J].中华中医药杂志,2023,38(9):4183-4186.
[4] 万德森.临床肿瘤学[M].北京:科学出版社,2019:300-302.
[5] 王娜.利妥昔单抗联合 CHOP 化疗方案治疗恶性淋巴瘤的效果观察[J].实用中西医结合临床,2021,21(7):85-87.
[6] 石远凯.中国恶性淋巴瘤诊疗规范[J].中华肿瘤杂志,2015,37(2):148-158.
[7] 王超,黄蓉.利妥昔单抗联合CHOP方案对弥漫大B细胞淋巴瘤患者血清PDGF-BB、LDH及三系血细胞的影响[J].临床医学研究与实践,2023,8(27):25-28.
[8] 袁佳蕾,陈钦开.人参皂甙Rg3抗肿瘤机制的研究进展[J].南昌大学学报(医学版),2019,59(5):96-98.
[9] 张淼,谭楠楠,姜泽丰,等.中药防治阿霉素心脏毒性的机制研究进展[J].中华老年心脑血管病杂志,2023,25(3):322-324.
[10] 周伟,杨莉洁.健脾祛痰方联合 R-CHOP 方案治疗高危弥漫大 B 细胞淋巴瘤疗效及对实验室血清学指标的影响[J].现代中西医结合杂志,2019,28(35):3937-3940.
[11] 徐瑞华,李进,马军,等.中国临床肿瘤学会常见恶性肿瘤诊疗指南[M].北京:人民卫生出版社,2022:737-819.
[12] 王永炎,彦世芸.实用中医内科学[M].上海:上海科学技术出版社,2020:702-708.
[13] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:207-224.
[14] 李去病,李勋,李森.瘤化平丸治疗肺癌120例疗效观察[J].陕西中医,2013,34(2):181-183.
[15] 赵倩,严香,张雅月.弥漫性大B细胞淋巴瘤的中医研究现状与思考[J].河北中医,2023,45(7):1218-1222.
[16] 冯彦铭,刘然,高宇,等.王晞星中医治疗恶性淋巴瘤经验探析[J].湖北中医杂志,2023,45(8):28-32.
[17] 陈姣,林聃,杨杰,等.中药抗肿瘤的增效减毒效应研究进展[J].中国科学:生命科学,2022,52(6):920-934.
[18] 姜成军,方美灵,吴静良,等.益气养阴中药改善癌痛患者生存质量30例观察[J].浙江中医杂志,2021,56(8):579-580.
[19] 张立双,张俊华,张晗,等.浅谈软坚散结法的内涵与外延[J].天津中医药大学学报,2021,40(2):137-141.
[20] 李蒙,郑相颖,李金根,等.蒽环类药物心脏毒性机制及新型心脏保护剂的研究进展[J].中国医药,2022,17(12):1880-1883.
[21] 罗纯生,展秀君,张俊玮,等.生化检测中肌酸激酶同工酶高于肌酸激酶的原因及对病情、心肌损伤程度的诊断分析[J].中国现代医生,2021,59(11):88-91.
[22] 罗旭,王千千,党会芬.血清乳酸脱氢酶与转移性胃癌姑息性化疗患者生存期的关系[J].兰州大学学报,2023,49(3):39-45.
[23] 王中会,晁旭,吕天依,等.土贝母苷甲抗肿瘤作用机制研究进展[J].陕西中医,2021,42(11):1652-1657.
[24] 查青,陈燕妮,晁旭.土贝母对小鼠肝癌的抑制作用及其机制[J].新乡医学院学报,2021,38(4):301-307.
[25] 莫琼,吴悠,韦迪,等.海洋药物牡蛎方剂用药规律分析[J].辽宁中医药大学学报,2022,24(2):203-208.
[26] 武美彤,张海欣,张梦,等.牡蛎酶解物对Lewis肺癌的抑制作用及机制[J].食品与发酵工业,2020,46(11):98-104,111.
[27] 沈金阳,张烜,于媛媛,等.海藻多肽的提取分离及抗肿瘤活性研究进展[J].河北大学学报(自然科学版),2023,43(4):379-386.
[28] 匡唐洪,汪静,刘云霞,等.中药复方联合化疗治疗恶性淋巴瘤的用药频数分析[J].中国中医药科技,2016,23(2):246-247.
[29] 景永帅,张钰炜,张丹参,等.大腹皮本草考证、化学成分和药理作用研究进展[J].中国药房,2021,32(14):1784-1788.

相似文献/References:

[1]王红英,方靖淞.健脾化瘀通腑方治疗恶性淋巴瘤化疗后肠梗阻脾虚肠燥证疗效研究[J].陕西中医,2024,(11):1512.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.015]
　WANG Hongying,FANG Jingsong.Study on curative effect of Jianpi Huayu Tongfu decoction in treatment of spleen deficiency and intestinal dryness obstruction after chemotherapy for malignant lymphoma[J].,2024,(7):1512.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.015]

备注/Memo

备注/Memo:
基金项目:陕西省中医药管理局科研项目(2021-ZZ-ZY013)
更新日期/Last Update: 2024-07-09